This post was originally published on this site

Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary IFM created to develop treatments targeting the cGAS and STING pathways, with an exclusive buyout option worth up to $840 million. Read more.

The post Novartis bankrolls IFM Due’s cGAS/STING pipeline—with $840M buyout option appeared first on Atlas Venture.